Lung; Disease, Interstitial, With FibrosisBPF GILDNCT03747627
BPF Genetics of ILD Study
An observational study of Lung; Disease, Interstitial, With Fibrosis and Alveolitis, Extrinsic Allergic, run by University of Dundee at 2 sites in United Kingdom.
Trial summary
The investigators aim to examine the genetic determinants of interstitial lung disease in a cohort of subjects with regular exposure to pigeons, a known cause of one form of interstitial lung disease known as hypersensitivity pneumonitis. Read more about this study
- Who is it for?
- Ages 18 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Lung; Disease, Interstitial, With Fibrosis, Alveolitis, Extrinsic Allergic, Bird Fancier's Lung
- What is being tested?
- Genetic profiling
- How many people
- 475 participants
- Where
- 2 sitesUnited Kingdom
- Study dates
- 19 Jan 2019to 19 Jan 2025
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Participants in the sport of Pigeon racing
Who may be able to join
- regular exposure to racing pigeons
Who cannot join
- Unwilling to participate
Trial locations and contacts
2 sites in 1 country.
United Kingdom2 sites
Royal Pigeon Racing Association Meeting
Blackpool, FY1 1HL
Scottish Homing Union
Lanark, ML11 9AX
About this study
Official title: British Pigeon Fanciers Genetics of Interstitial Lung Disease Study
The investigators aim to examine the genetic determinants of interstitial lung disease in a cohort of subjects with regular exposure to pigeons, a known cause of one form of interstitial lung disease known as hypersensitivity pneumonitis. In addition we will examine immunological causes for hypersensitivity pneumonitis in this group.
We anticipate our work will provide insights of use to clinicians and patients with hypersensitivity pneumonitis and other interstitial lung diseases.
Read the detailed description
The investigators aim to recruit participants with regular racing pigeon exposure at national (UK) and regional pigeon fancier meetings.
Consenting subjects will complete questionnaires, provide blood samples for genetic analysis and immunological testing and undertake lung function measurements.
Subjects will be observed, and encouraged to report referral to specialist respiratory services, and following this information will be sought on diagnosis (including supporting evidence). Where interstitial lung disease is detected this will be linked to subsequent unbiased analysis to detect potential predisposing genetic associations.
- Conditions
- Lung; Disease, Interstitial, With Fibrosis, Alveolitis, Extrinsic Allergic, Bird Fancier's Lung, Idiopathic Interstitial Pneumonias, Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis
- Being tested
- Genetic profiling
- Keywords
- Interstitial Lung Disease (ILD), Hypersensitivity Pneumonitis, Idiopathic Pulmonary Fibrosis (IPF), Extrinsic Allergic Alveolitis (EAA), Bird Fancier's Lung, Genetics
- Medical subject headings
- Disease, Alveolitis, Extrinsic Allergic, Bird Fancier's Lung, Idiopathic Interstitial Pneumonias, Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Genetic profilingDiagnostic test
All participating subjects will undergo detailed genetic analysis, with the aim of detecting novel genetic drivers for the development of interstitial lung disease in the context of known sensitising agent (pigeon antigen)
What is being measured
The primary outcome is the main question the study is designed to answer.
Relationship of specific genetic markers to development of interstitial lung disease
Participants will be screened for MUC5B genetic profile to allow examination of MUC5B genetic profile relationship with risk of developing interstitial lung disease in this group
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Nov 2018
- Study start19 Jan 2019
- Primary completion19 Jan 2025
- Study completion19 Jan 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung; Disease, Interstitial, With FibrosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 475 participants (actual)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- University of Dundee
- Sponsor type
- University, hospital or other
- Collaborators
- University of Leicester, University of Glasgow, Newcastle University, British Lung Foundation, British Pigeon Fanciers Medical Research
- Responsible party
- Principal investigator, Mark Spears, University of Dundee
- Investigators
- Mark Spears, PhD, FRCP, Principal investigator, NHS Tayside & University of DundeeLouise Wain, PhD, Principal investigator, University of Leicester
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03747627
- Sponsor's protocol ID
- MS001
- Acronym
- BPF GILD
- Status last verified
- May 2026
- First submitted
- 14 Nov 2018
- Last updated
- 27 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Will be considered, dependent on potential for increased power
Study at a glance
From the registry record, last updated by the sponsor on 27 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- British Pigeon Fanciers Genetics of Interstitial Lung Disease Study
- ClinicalTrials.gov ID
- NCT03747627
- Acronym / sponsor ID
- BPF GILD / MS001
- Conditions
- Lung; Disease, Interstitial, With Fibrosis, Alveolitis, Extrinsic Allergic, Bird Fancier's Lung, Idiopathic Interstitial Pneumonias, Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis
- Keywords
- Interstitial Lung Disease (ILD), Hypersensitivity Pneumonitis, Idiopathic Pulmonary Fibrosis (IPF), Extrinsic Allergic Alveolitis (EAA), Bird Fancier's Lung, Genetics
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 475 participants (actual)
- Lead sponsor
- University of DundeeUniversity, hospital or other
- Collaborators
- University of Leicester, University of Glasgow, Newcastle University, British Lung Foundation, British Pigeon Fanciers Medical Research
- Study start
- 19 Jan 2019 (actual)
- Primary completion
- 19 Jan 2025 (actual)
- Study completion
- 19 Jan 2025 (actual)
- First posted
- 20 Nov 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators aim to examine the genetic determinants of interstitial lung disease in a cohort of subjects with regular exposure to pigeons, a known cause of one form of interstitial lung disease known as hypersensitivity pneumonitis. In addition we will examine immunological causes for hypersensitivity pneumonitis in this group.
We anticipate our work will provide insights of use to clinicians and patients with hypersensitivity pneumonitis and other interstitial lung diseases.
Detailed description
The investigators aim to recruit participants with regular racing pigeon exposure at national (UK) and regional pigeon fancier meetings.
Consenting subjects will complete questionnaires, provide blood samples for genetic analysis and immunological testing and undertake lung function measurements.
Subjects will be observed, and encouraged to report referral to specialist respiratory services, and following this information will be sought on diagnosis (including supporting evidence). Where interstitial lung disease is detected this will be linked to subsequent unbiased analysis to detect potential predisposing genetic associations.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 5 Years
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Participants in the sport of Pigeon racing
Key inclusion criteria (1 listed)
- regular exposure to racing pigeons
Key exclusion criteria (1 listed)
- Unwilling to participate
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Genetic profilingAll participating subjects will undergo detailed genetic analysis, with the aim of detecting novel genetic drivers for the development of interstitial lung disease in the context of known sensitising agent (pigeon antigen) | Diagnostic test | – |
Primary outcome
Relationship of specific genetic markers to development of interstitial lung disease
Time frame: 5 years
Participants will be screened for MUC5B genetic profile to allow examination of MUC5B genetic profile relationship with risk of developing interstitial lung disease in this group
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 May 2026.
- Individual participant dataSharing planned: Undecided. Will be considered, dependent on potential for increased power
Related trials for Lung; Disease, Interstitial, With Fibrosis
Active, not recruitingPhase 2
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
Idiopathic Pulmonary Fibrosis
RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
RecruitingPhase 3
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial
Interstitial Lung Disease (ILD), Suspected Interstitial Lung Disease
Active, not recruitingObservational study
Analysis of Specimens From Individuals With Pulmonary Fibrosis
Pulmonary Fibrosis, Healthy Volunteers
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mark Spears, PhD, FRCP principal investigator
NHS Tayside & University of Dundee
Louise Wain, PhD principal investigator
University of Leicester
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung; Disease, Interstitial, With Fibrosis and Alveolitis, Extrinsic Allergic, run by University of Dundee at 2 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Relationship of specific genetic markers to development of interstitial lung disease (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 May 2026.